
Jordi Barretina Ginesta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4060995/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The effect of external stimulation on functional networks in the aging healthy human brain. Cerebral Cortex, 2022, 33, 235-245.	2.9	8
2	Whole-Brain Dynamics in Aging: Disruptions in Functional Connectivity and the Role of the Rich Club. Cerebral Cortex, 2021, 31, 2466-2481.	2.9	29
3	E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. Oncogene, 2021, 40, 6614-6626.	5.9	7
4	Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nature Communications, 2021, 12, 6946.	12.8	22
5	The Aging Imageomics Study: rationale, design and baseline characteristics of the study population. Mechanisms of Ageing and Development, 2020, 189, 111257.	4.6	18
6	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene, 2019, 38, 6399-6413.	5.9	160
7	Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. International Journal of Cancer, 2019, 145, 3321-3333.	5.1	16
8	Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature, 2019, 569, 503-508.	27.8	2,149
9	The landscape of cancer cell line metabolism. Nature Medicine, 2019, 25, 850-860.	30.7	350
10	Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nature Communications, 2018, 9, 4181.	12.8	77
11	EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. Cancer Research, 2016, 76, 1591-1602.	0.9	103
12	Identification of ALK Gene Alterations in Urothelial Carcinoma. PLoS ONE, 2014, 9, e103325.	2.5	9
13	An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules. Cell, 2013, 154, 1151-1161.	28.9	615
14	Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1386-1391.	21.4	238
15	Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges. Journal of Clinical Oncology, 2013, 31, 1874-1884.	1.6	101
16	NF1 Deletion Generates Multiple Subtypes of Soft-Tissue Sarcoma That Respond to MEK Inhibition. Molecular Cancer Therapeutics, 2013, 12, 1906-1917.	4.1	73
17	Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis. Cancer Research, 2012, 72, 4383-4393.	0.9	242
18	Melanoma genome sequencing reveals frequent PREX2 mutations. Nature, 2012, 485, 502-506.	27.8	671

#	Article	IF	CITATIONS
19	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. Clinical Cancer Research, 2012, 18, 4997-5007.	7.0	251
20	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature, 2012, 483, 603-607.	27.8	6,473
21	Nuclear factor I/B is an oncogene in small cell lung cancer. Genes and Development, 2011, 25, 1470-1475.	5.9	142
22	Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature, 2011, 476, 346-350.	27.8	1,359
23	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genetics, 2011, 43, 964-968.	21.4	270
24	Advances in sarcoma genomics and new therapeutic targets. Nature Reviews Cancer, 2011, 11, 541-557.	28.4	364
25	Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12372-12377.	7.1	383
26	Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without <i>IGF1R</i> genomic amplification. International Journal of Cancer, 2010, 127, 2718-2722.	5.1	62
27	The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463, 899-905.	27.8	3,331
28	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 2010, 468, 968-972.	27.8	1,325
29	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 2010, 42, 715-721.	21.4	642
30	Integrative analysis of the melanoma transcriptome. Genome Research, 2010, 20, 413-427.	5.5	248
31	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biology and Therapy, 2009, 8, 2042-2050.	3.4	78
32	Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling. Cancer Cell, 2009, 16, 115-125.	16.8	411
33	The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nature Genetics, 2009, 41, 882-884.	21.4	616
34	Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions. Journal of Clinical Investigation, 2009, 119, 1727-1740.	8.2	230
35	CDK8 is a colorectal cancer oncogene that regulates Î ² -catenin activity. Nature, 2008, 455, 547-551.	27.8	594
36	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. Cancer Research, 2008, 68, 6779-6788.	0.9	589

#	Article	IF	CITATIONS
37	CDYL Bridges REST and Histone Methyltransferases for Gene Repression and Suppression of Cellular Transformation. Molecular Cell, 2008, 32, 718-726.	9.7	133
38	Functional Copy-Number Alterations in Cancer. PLoS ONE, 2008, 3, e3179.	2.5	142
39	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20007-20012.	7.1	927
40	High-throughput oncogene mutation profiling in human cancer. Nature Genetics, 2007, 39, 347-351.	21.4	927
41	R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. Journal of Leukocyte Biology, 2004, 76, 804-811.	3.3	51
42	Immunological and virological study of enfuvirtide-treated HIV-positive patients. Aids, 2004, 18, 1673-1682.	2.2	31
43	High Level of Coreceptor-independent HIV Transfer Induced by Contacts between Primary CD4 T Cells. Journal of Biological Chemistry, 2004, 279, 51305-51314.	3.4	89
44	Cell-Surface-Expressed HIV-1 Envelope Induces the Death of CD4 T Cells during GP41-Mediated Hemifusion-like Events. Virology, 2003, 305, 318-329.	2.4	70
45	Interleukin-7-Dependent Production of RANTES That Correlates with Human Immunodeficiency Virus Disease Progression. Journal of Virology, 2003, 77, 4389-4395.	3.4	23
46	Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antiviral Therapy, 2003, 8, 155-61.	1.0	7
47	Anti-HIV-1 Activity of Enfuvirtide (T-20) by Inhibition of Bystander Cell Death. Antiviral Therapy, 2003, 8, 155-161.	1.0	25
48	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. Antiviral Therapy, 2003, 8, 1-8.	1.0	51
49	Preferential Attachment of HIV Particles to Activated and CD45RO+CD4+T Cells. AIDS Research and Human Retroviruses, 2002, 18, 27-38.	1.1	12
50	Anti-HIV activity of a novel aminoglycoside-arginine conjugate. Antiviral Research, 2002, 53, 1-8.	4.1	31
51	Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO Journal, 2002, 21, 4070-4080.	7.8	146
52	Interleukin-7 in Plasma Correlates with CD4 T-Cell Depletion and May Be Associated with Emergence of Syncytium-Inducing Variants in Human Immunodeficiency Virus Type 1-Positive Individuals. Journal of Virology, 2001, 75, 10319-10325.	3.4	127
53	CD4+ and CD8+ T Cell Death during Human Immunodeficiency Virus Infection in Vitro. Virology, 2001, 285, 356-365.	2.4	19
54	Human Immunodeficiency Virus 1 Envelope Glycoprotein Complex-Induced Apoptosis Involves Mammalian Target of Rapamycin/Fkbp12-Rapamycin–Associated Protein–Mediated P53 Phosphorylation. Journal of Experimental Medicine, 2001, 194, 1097-1110.	8.5	147

#	Article	IF	CITATIONS
55	Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo. Aids, 2001, 15, 1890-1892.	2.2	15
56	The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelope-Induced Apoptosis. Antimicrobial Agents and Chemotherapy, 2000, 44, 51-56.	3.2	59
57	Anti-Human Immunodeficiency Virus Activity of Novel Aminoglycoside-Arginine Conjugates at Early Stages of Infection. AIDS Research and Human Retroviruses, 2000, 16, 627-634.	1.1	36